Abstracts Archive - Page 1622 of 2425 - ACR Meeting Abstracts

Abstract Number: 3075 • 2016 ACR/ARHP Annual Meeting
Mitochondrial Genetic Variation, Copy Number and Susceptibility to Gout in the New Zealand Polynesian Population
Tony R. Merriman¹, James Boocock², Nicola Dalbeth³, Lisa K. Stamp⁴, Eli A. Stahl⁵, Hyon K. Choi⁶, Elizabeth Matisoo-Smith⁷ and Anna Gosling⁸, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ⁷Anatomy, University of Otago, Dunedin, New Zealand, ⁸Biochemistry, University of Otago, Dunedin, New Zealand
Background/Purpose: Mitochondria play a central role in induction of an NLRP3 inflammatory response essential for gouty pathology. Mitochondria are in part self-encoding, possessing a 16.5…
Abstract Number: 3076 • 2016 ACR/ARHP Annual Meeting
Development of a Matrix-Binding Interlukin-1 Receptor Antagonist Fusion Protein for Extended Retention in the Joint Tissues
James Pancoast¹, Richard Lee^2,3 and Parth Patwari¹, ¹ProteoThera, Inc., Newton, MA, ²Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, ³Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: A primary challenge for intra-articular delivery of protein and peptide therapies has been their short residence time in the joint tissues. The IL-1 receptor…
Abstract Number: 3077 • 2016 ACR/ARHP Annual Meeting
Quiescence in Active and Inactive Non-Infectious, Intermediate, Posterior, or Panuveitis in Patients Treated with Adalimumab
Robert Landewé¹, Irene van der Horst-Bruinsma², Samir Tari³, Stefan Florentinus³, Alexandra P. Song³, Martina Kron⁴, Sophia Pathai⁵ and James T. Rosenbaum^6,7, ¹University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁵AbbVie Ltd, Maidenhead, United Kingdom, ⁶Casey Eye Institute, Oregon Health & Science University, Portland, OR, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: There is an unmet need for effective therapies for patients (pts) with non-infectious intermediate, posterior, or panuveitis who are at risk for long-term side…
Abstract Number: 3078 • 2016 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis and Diabetes- Using Genetic Risk Scores to Explore the Association
Melissa Wang¹, Mariko Ishimori², Greg Kinney³, Irina Ianculsecu¹, Elizabeth Regan⁴, Michael Weisman⁵ and Mark Goodarzi⁶, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Medicine, National Jewish Health, Denver, CO, ⁵Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ⁶Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) is a poorly understood condition characterized by new bone formation mainly affecting the spine. An association of DISH with…
Abstract Number: 3079 • 2016 ACR/ARHP Annual Meeting
The Characteristic Features of the Patients with Deficiency of Adenosine Deaminase 2 (DADA2)
Abdulsamet Erden¹, Ezgi Deniz Batu², Ekim Z. Taskiran³, Hafize Emine Sonmez², Alper Sari¹, Berkan Armagan¹, Levent Kilic¹, Zehra Serap Arıcı⁴, Yelda Bilginer⁵, Ali Akdogan¹, Omer Karadag¹, Umut Kalyoncu¹ and Seza Ozen^6,7, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Department of Medical Genetics, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ⁴Departments of Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Departments of Pediatric Nephrology and Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁶Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disease resulting from a loss-of-function mutation in Cat Eye Syndrome Chromosome Region Candidate…
Abstract Number: 3080 • 2016 ACR/ARHP Annual Meeting
Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg
Laura Cappelli¹, Anna Kristina Gutierrez², Alan N. Baer², Jemima Albayda³, Rebecca L. Manno², Uzma Haque³, Ami A. Shah³, Evan Lipson⁴, Karen Bleich⁵, Julie Brahmer⁴, Patrick Forde⁴, Dung Le⁶, Jarushka Naidoo⁴ and Clifton Bingham III⁷, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD
Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg Background/Purpose: Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed…
Abstract Number: 3081 • 2016 ACR/ARHP Annual Meeting
Prognostic Factors of Death in a Cohort of 116 Adults with Hemophagocytic Syndrome: Impact of Underlying Disease and Laboratory Parameters
Pilar Brito-Zerón¹, Pedro Moral Moral², Belchin Kostov³, Luis Caminal-Montero⁴, Guadalupe Fraile⁵, Eva Fonseca⁶, Patricia Pérez Guerrero⁷, Angel Robles⁸, Antonio J. Chamorro⁹, María Andrés Calvo¹⁰, José Ramón Larrañaga¹¹, Maria José Forner¹², Mónica Rodriguez Carballeira¹³, Manuel Ruiz Muñoz¹⁴, Roberto Hurtado García¹⁵, Luis Fernando Viejo Llorente¹⁶, Sergio Prieto-González¹⁷, Pedro Castro¹⁸, Aleida Martínez Zapico⁴, María Vaquero Herrero⁹, Angela Ruiz de Temiño de la Peña¹⁰, Soledad Retamozo^1,19, Manuel Ramos-Casals²⁰ and REGHEM-GEAS-SEMI Spanish Cohort, ¹Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ²Department of Internal Medicine, Hospital La Fé, Valencia, Valencia, Spain, ³Research Group in Primary Care, IDIBAPS, ABS Les Corts, CAPSE, Barcelona, Spain, ⁴Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁵Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ⁶Department of Internal Medicine, Hospital de Cabueñes, Gijón, Gijón, Spain, ⁷Department of Internal Medicine, Hospital Universitario Puerta del Mar, Cádiz, Cadiz, Spain, ⁸Department of Internal Medicine, Hospital La Paz, Madrid, Madrid, Spain, ⁹Department of Internal Medicine, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ¹⁰Department of Internal Medicine, Hospital Rio Hortega, Valladolid, Valladolid, Spain, ¹¹Department of Internal Medicine, Hospital Xeral, Vigo, Vigo, Spain, ¹²Department of Internal Medicine, Hospital Clínico de Valencia, Valencia, Spain, ¹³Department of Internal Medicine, Hospital Mutua de Terrasa, Terrasa, Spain, ¹⁴Department of Internal Medicine, Hospital Universitario Fundacion Alcorcón, Madrid, Spain, ¹⁵Department of Internal Medicine, Hospital Vega Baja, Orihuela, Orihuela, Spain, ¹⁶Department of Internal Medicine, Hospital Virgen de la Salud, Toledo, Toledo, Spain, ¹⁷Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁸Medical Intensive Care Unit, ICMiD, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ²⁰Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: To analyze the potential use of the main features at diagnosis (epidemiological, clinical, laboratory) as prognostic factors and to estimate the risk of death…
Abstract Number: 3082 • 2016 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome Is Identified By Coagulopathy, Hyperferritinemia, Fever, and Cytopenia in Hospitalized Patients, Resulting in Poor Outcome
Bita Shakoory¹, Negin Mohtasham², Matthew Mullen³, Richard Amdur⁴ and W. Winn Chatham⁵, ¹None, MCLEAN, VA, ²Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), ³Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Surgery, George Washington University, Washington, DC, ⁵Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Macrophage activation syndrome (MAS) constitutes over 5% of multi-organ dysfunction syndrome in adults, leading to 60-70% mortality without early treatment. H-Score, the only validated…
Abstract Number: 3083 • 2016 ACR/ARHP Annual Meeting
Utility of Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Short Form for Understanding Interplay Between Patient-Reported Outcome Measures and Physician Driven Disease Activity Measures
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng², Jason Lyons², Anthony Fabio² and Larry W. Moreland¹, ¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsburgh, School of Public Health, Pittsburgh, PA
Background/Purpose: Discordance between patient and physician assessment of rheumatoid arthritis (RA) disease activity strongly associates with pain scores. Patient-reported outcomes measurement information system (PROMIS) 29…
Abstract Number: 3084 • 2016 ACR/ARHP Annual Meeting
The Impact of Mental Health on Indicators of Disease Severity Among Patients with Inflammatory Arthritis: A Cross-Sectional and Longitudinal Investigation
Renee El-Gabalawy¹, Mathew Bernstein², Cory Mackenzie³, Jitender Sareen⁴ and Carol Hitchon⁵, ¹Clinical Health Psychology and Anesthesia & Perioperative Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Clinical Psychology, University of Manitoba, Winnipeg, MB, Canada, ³Psychology, University of Manitoba, Winnipeg, MB, Canada, ⁴Psychiatry, University of Manitoba, Winnipeg, MB, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid arthritis, is the leading cause of disability and chronic pain. Psychiatric disorders such as depression and anxiety adversely impact reported pain and may…
Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Brigitte Michelsen^1,2, Karen M Fagerli¹, Elisabeth Lie¹, Hilde Berner Hammer³, Glenn Haugeberg^4,5, Eirik K Kristianslund¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…
Abstract Number: 3086 • 2016 ACR/ARHP Annual Meeting
Changing Patterns over Time in Opiate Use in U.S. Rheumatoid Arthritis Patients
Jeffrey Curtis¹, Fenglong Xie², Kenneth Saag³, Lang Chen², Timothy Beukelman⁴, Melissa Mannion⁵ and Huifeng Yun⁶, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatric Rheumatology, University of Alabama-Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Opiate use has come under increasing scrutiny related both to over-use and under-use. The patterns of opiate use over time in a population-based cohort…
Abstract Number: 3087 • 2016 ACR/ARHP Annual Meeting
Association of Weight Loss with Improved Disease Activity in Patients with Rheumatoid Arthritis
David J. Kreps^1,2, Florencia Halperin³, Sonali P. Desai³, Zhi Zhang³, Elena Losina³, Elizabeth W. Karlson¹, Bonnie L. Bermas¹ and Jeffrey A. Sparks⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Boston University, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose : Obesity has been associated with worsened RA outcomes and increased disease activity. However, few longitudinal studies have investigated whether weight loss might improve…
Abstract Number: 3088 • 2016 ACR/ARHP Annual Meeting
Predictors of Non-Adherence with Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Vandana Ahluwalia¹, Mohammad Movahedi^2,3, Emmanouil Rampakakis², Angela Cesta³, Xiuying Li³, John S. Sampalis⁴ and Claire Bombardier⁵, ¹Brampton Civic Hospital, Brampton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite the availability of safe and effective treatments and the establishment of treatment guidelines, real-world effectiveness remains suboptimal largely due to low patient adherence…
Abstract Number: 3089 • 2016 ACR/ARHP Annual Meeting
Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis
Duncan Porter¹, C. S. Goodyear², J. S. Nijjar¹, Martina Messow³, Stefan Siebert¹, Manikhandan Mudaliar⁴ and Iain B. McInnes⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom, ⁴Glasgow Polyomics Facility, University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain
Background/Purpose: The ORBIT study demonstrated that rituximab is non-inferior to a TNFi-first strategy in biologic naive, sero-positive patients with active RA over 12 months (Lancet…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].